Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Simcere Pharmaceuticals Forges Global Drug Discovery Alliance with Schrödinger – Combining Computational Platform with Therapeutic Expertise

Fineline Cube Jul 10, 2026
Company Deals

Conba Pharmaceutical Secures Greater China Rights to Cebranopadol – First-in-Class Dual-Target Analgesic from Adneuris Therapeutics

Fineline Cube Jul 10, 2026
Company Deals

Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST

Fineline Cube Jul 9, 2026
Company Deals

Xenovector and Jilin University Launch Strategic Partnership to Advance Gene-Edited Pig Organ Transplantation from Breakthrough to Affordable Healthcare

Fineline Cube Jul 9, 2026
Company Deals

Zhejiang Hisun Pharmaceutical and Tigermed Forge Strategic Alliance to Create End-to-End Innovative Drug Development Pipeline

Fineline Cube Jul 9, 2026
Policy / Regulatory

China’s National Health Commission Unveils 2026 Essential Medicines List, Adding 116 New Drugs with Full Insurance Coverage

Fineline Cube Jul 9, 2026
Company Drug

Jacobio Pharma’s Incubator Secures NMPA IND Clearance for JAR-2203 Injection – Novel Therapy Targeting Hyperlipoproteinemia(a)

Fineline Cube Jul 10, 2026
Company Drug

Haixi Pharma Launches Phase III Trial of C019199 – First-in-Class Multi-Targeted Immunomodulator for Refractory Osteosarcoma

Fineline Cube Jul 10, 2026
Company Drug

Gilead’s Kite Receives FDA Nod to Add Overall Survival Data to Yescarta for Large B-Cell Lymphoma

Fineline Cube Dec 29, 2023

Gilead Sciences Inc. (NASDAQ: GILD) subsidiary Kite has received approval from the U.S. Food and...

Company Drug

FDA Prioritizes Roche’s Xolair for Food Allergy Indication Extension Ahead of Q1 Decision

Fineline Cube Dec 29, 2023

The U.S. Food and Drug Administration (FDA) has prioritized Roche’s (SWX: ROG) indication extension filing...

Company Drug

Lepu Biotechnology Completes Enrollment for Phase IIb Trial of MRG003 in Nasopharyngeal Carcinoma

Fineline Cube Dec 29, 2023

Lepu Biotechnology Co., Ltd (HKG: 2157), based in China, has announced the completion of subject...

Company Medical Device

Sino Medical Secures Approvals for Key Coronary Devices in Taiwan, India, and Uzbekistan

Fineline Cube Dec 29, 2023

Sino Medical Sciences Technology Inc. (SHA: 688108), a China-based medical device company, has announced that...

Company Drug

Shanghai Henlius Secures Indonesian Approval for HanSiZhuang in Small-Cell Lung Cancer

Fineline Cube Dec 29, 2023

Shanghai Henlius Biotech Inc. (HKG: 2696) has received market approval from the Indonesian Food and...

Company Deals

IVD Medical Ends Strategic Partnership with Japan’s Sysmex in Coagulation Products

Fineline Cube Dec 29, 2023

IVD Medical Holding Ltd (HKG: 1931), a China-based in vitro diagnostic (IVD) specialist, has announced...

Company Drug

Clover Biopharma’s SCB-219M Shows Promising Phase I Results for Chemotherapy-Induced Thrombocytopenia

Fineline Cube Dec 29, 2023

Clover Biopharmaceuticals Ltd (HKG: 2197), based in China, has announced promising preliminary results from its...

Company Deals

Eli Lilly Completes Acquisition of Point Biopharma, Expanding Radiopharmaceutical Portfolio

Fineline Cube Dec 28, 2023

Eli Lilly (NYSE: LLY) has finalized its acquisition of radiopharmaceutical company Point Biopharma (NASDAQ: PNT)...

Company Drug

Fosun’s HLX42 Receives Fast-Track Designation from FDA for NSCLC Treatment

Fineline Cube Dec 28, 2023

Fosun Pharmaceutical (Group) Co., Ltd. (HKG: 2196; SHA: 600196) has announced that its antibody-drug conjugate...

Company Deals

CATUG Biotechnology Partners with PersonGen to Advance Global CAR-T Cell Therapies

Fineline Cube Dec 28, 2023

China-based CATUG Biotechnology (Suzhou) Co., Ltd. has entered into a partnership with fellow Suzhou firm...

Company Medical Device

Cryofocus Medtech Secures NMPA Approval for Cryotherapy Equipmen

Fineline Cube Dec 28, 2023

Shanghai-based Cryofocus Medtech (Shanghai) Co., Ltd. (HKG: 6922) has announced that it has received marketing...

Company Drug

Simcere Secures Approval for Local Manufacturing of Cosela, Boosting Patient Access

Fineline Cube Dec 28, 2023

China-based Simcere Pharmaceutical Group (HKG: 2096) has received supplementary filing approval for its drug Cosela...

Company

Chengda Pharmaceuticals Halts Shanghai Research Project Amid Market Challenges

Fineline Cube Dec 28, 2023

Chengda Pharmaceuticals Co. Ltd. (SHE: 301201), based in China, has announced the termination of its...

Company Deals

TYK Medicines Secures Nearly RMB 200 Million in Series D Financing Led by Sichuan Huiyu Pharmaceutical

Fineline Cube Dec 28, 2023

Shanghai-based TYK Medicines (HKG: 2410) has successfully completed a Series D financing round, raising nearly...

Company Medical Device

NMPA Approves Pulnovo Medical’s Novel Catheter for Treating Pulmonary Arterial Hypertension

Fineline Cube Dec 28, 2023

The National Medical Products Administration (NMPA) has granted marketing approval for Pulnovo Medical’s disposable circular...

Company Deals

Innovent Biologics Partners with Xuanzhu Biopharma for Clinical Trial of Sintilimab and KM-501 in Advanced Tumors

Fineline Cube Dec 28, 2023

Innovent Biologics, Inc. (HKG: 1801), based in China, has entered into a clinical trial collaboration...

Company Drug

Sanofi Gains NMPA Approval for Innovative Rosuvastatin and Ezetimibe Combination Therapy

Fineline Cube Dec 28, 2023

Sanofi (NASDAQ: SNY), the French pharmaceutical giant, has announced that it has received market approval...

Company Deals

Janssen Acquires Rights to Gene Therapy Botaretigene Sparoparvovec from MeiraGTx for XLRP Treatment

Fineline Cube Dec 28, 2023

Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson (J&J, NYSE: JNJ), announced last week its...

Company Drug

AstraZeneca Secures FDA Approval for Self-Administered hATTR-PN Therapy Wainua

Fineline Cube Dec 28, 2023

AstraZeneca (AZ, NASDAQ: AZN), headquartered in the UK, announced last week that the U.S. Food...

Company Deals

Elpiscience Partners with Astellas for Bi-Specific Macrophage Engager Research

Fineline Cube Dec 28, 2023

China-based Elpiscience Biopharmaceuticals has announced a research collaboration and licensing agreement with Japan’s Astellas Pharma...

Posts pagination

1 … 450 451 452 … 693

Recent updates

  • Simcere Pharmaceuticals Forges Global Drug Discovery Alliance with Schrödinger – Combining Computational Platform with Therapeutic Expertise
  • Conba Pharmaceutical Secures Greater China Rights to Cebranopadol – First-in-Class Dual-Target Analgesic from Adneuris Therapeutics
  • Jacobio Pharma’s Incubator Secures NMPA IND Clearance for JAR-2203 Injection – Novel Therapy Targeting Hyperlipoproteinemia(a)
  • Haixi Pharma Launches Phase III Trial of C019199 – First-in-Class Multi-Targeted Immunomodulator for Refractory Osteosarcoma
  • Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Simcere Pharmaceuticals Forges Global Drug Discovery Alliance with Schrödinger – Combining Computational Platform with Therapeutic Expertise

Company Deals

Conba Pharmaceutical Secures Greater China Rights to Cebranopadol – First-in-Class Dual-Target Analgesic from Adneuris Therapeutics

Company Drug

Jacobio Pharma’s Incubator Secures NMPA IND Clearance for JAR-2203 Injection – Novel Therapy Targeting Hyperlipoproteinemia(a)

Company Drug

Haixi Pharma Launches Phase III Trial of C019199 – First-in-Class Multi-Targeted Immunomodulator for Refractory Osteosarcoma

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.